Decrease in the evoked release of endogenous dopamine and dihydroxyphenylacetic acid from rat striatal slices after withdrawal from repeated haloperidol
- PMID: 2086236
- DOI: 10.1016/0014-2999(90)94142-k
Decrease in the evoked release of endogenous dopamine and dihydroxyphenylacetic acid from rat striatal slices after withdrawal from repeated haloperidol
Abstract
The release of endogenous DA (dopamine) and DOPAC (3,4-dihydroxyphenylacetic acid) from rat striatal slices was measured after withdrawal from a prior long-term treatment of the rat with haloperidol to investigate adaptive changes in striatal DA and DOPAC release induced by chronic haloperidol treatment. Striatal slices prepared 24 h after the last injection of daily treatment with haloperidol for up to 14 days (2.5 mg/kg per day) were superfused and stimulated for 5 min with K+ (50 mM). Haloperidol treatment for 3 or 7 days decreased K(+)-stimulated DA release by maximally 35%, but a 14-day treatment was not effective. The K(+)-stimulated release of DOPAC, which occurred after the change in DA release, was reduced significantly by the treatment for 7 or 14 days. A higher daily dose of haloperidol (10 mg/kg per day) produced a more pronounced decrease in stimulated DA release after a 14-day treatment without having an effect after 3 days. However, the stimulated release of DOPAC decreased markedly after both 3 and 14 days of haloperidol treatment. The slight reduction in the DA content of the slices after K+ stimulation was seen in some haloperidol-treated tissues, although this change did not always parallel the simultaneous decrease in DA release. These results indicate that the K(+)-induced stimulation of endogenous DA release and the synthesis of DA are impaired after withdrawal from repeated haloperidol treatment.
Similar articles
-
Release of endogenous dopamine, 3,4-dihydroxyphenylacetic acid, and amino acid transmitters from rat striatal slices.Neurochem Res. 1985 Apr;10(4):515-27. doi: 10.1007/BF00964655. Neurochem Res. 1985. PMID: 2860579
-
Alterations in dopamine release from striatal slices of rats after chronic treatment with haloperidol.Eur J Pharmacol. 1991 Jan 3;192(1):141-5. doi: 10.1016/0014-2999(91)90080-a. Eur J Pharmacol. 1991. PMID: 2040357
-
Ceruletide, a cholecystokinin-related peptide, attenuates haloperidol-induced increase in dopamine release from the rat striatum: an in vivo microdialysis study.Brain Res. 1990 Jun 11;519(1-2):44-9. doi: 10.1016/0006-8993(90)90058-j. Brain Res. 1990. PMID: 2397417
-
Development of haloperidol-induced dopamine release in the rat striatum using intracerebral dialysis.J Neurochem. 1990 Jan;54(1):181-6. doi: 10.1111/j.1471-4159.1990.tb13299.x. J Neurochem. 1990. PMID: 2293609
-
Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens.J Pharmacol Exp Ther. 1991 Jan;256(1):348-57. J Pharmacol Exp Ther. 1991. PMID: 1703232
MeSH terms
Substances
LinkOut - more resources
Full Text Sources